Vivesto — Capital/Financing Update 2010

Nov 25, 2010

News Details

Ad-hoc | 25 November 2010 08:23

Oasmia Pharmaceutical completes rights issue of SEK 238.7 million

Oasmia Pharmaceutical AB

25.11.2010 08:23

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

PRESS RELEASE November 25, 2010

Oasmia Pharmaceutical completes rights issue of SEK 238.7 million

Through the rights issue, Oasmia Pharmaceutical AB (publ) ('Oasmia') has
received proceeds amounting to approximately SEK 238.7 million before
transaction related costs. Of the proceeds SEK 70 million have been paid by the
main shareholder Oasmia S.A. by offsetting the equivalent amount against its
claim against the company.
The final result of the rights issue of Oasmia shows that 12,899,278 new shares,
representing approximately 89 percent of the shares offered, were subscribed for
by the exercise of subscription rights.
Another 518 651 shares corresponding to approximately 4 percent of the shares
offered have been subscribed for without subscription rights and have been
allotted to those who have subscribed in accordance with the principles set out
in the prospectus.
The remaining 1?048 554 shares corresponding to approximately 7 percent of the
shares offered have been allotted to those who have entered into guarantee
commitments with Oasmia in accordance with each respective agreement.
Notification regarding allotment of shares that have been subscribed for without
subscription rights will be sent to those who have been allotted shares.
Through the rights issue Oasmia's share capital increases by SEK 1?446 648.30 to
SEK 5?207 934.10. The number of shares increases by 14?466 483 to 52?079 341.
The last day for trading in paid subscribed shares (BTA) on NASDAQ OMX Stockholm
is expected to be December 1, 2010. New shares subscribed for with and without
subscription rights are expected to start trading on NASDAQ OMX Stockholm on
December 9, 2010.

IMPORTANT INFORMATION
The information in this press release is not intended, directly or indirectly,
for release, publication or distribution, in or into the United States, Canada,
Ireland, Switzerland, South Africa, Japan, Hong Kong, Singapore, Australia or
New Zeeland.
The information in this press release does not and shall not be deemed to
constitute an offer to sell, or a solicitation to buy, nor shall there be any
sale of the securities referred to herein in any jurisdiction in which such
offer, solicitation or sale would require preparation of further prospectuses or
other offer documentation, or would be unlawful prior to registration or absent
an applicable exemption from registration requirements under the securities laws
of any such jurisdiction.
The information in this press release is not, and does not constitute or form a
part of any offer or solicitation to buy or to subscribe for securities in the
United States. The securities mentioned herein have not been, and will not be,
registered under the United States Securities Act of 1933 (the 'Securities
Act'). The securities mentioned herein may not be offered or sold in the United
States except pursuant to an exemption from the registration requirements of the
Securities Act. There will be no public offering of securities in the United
States.
The information in this press release may not be forwarded or distributed to any
other person and may not be reproduced in any manner whatsoever. Any
transmission, forwarding, distribution, reproduction, or disclosure of this
information, in whole or in part, is unauthorized. Failure to comply with this
directive may result in a violation of the Securities Act or the applicable laws
of other jurisdictions. The above information has been made public by Oasmia in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 08.30 AM CET on November 25, 2010.
Oasmia has not decided to offer shares or subscription rights to the public in
any other member state within the European Economic Area, with the exception of
Sweden. Within such member states of the European Economic Area (except for
Sweden) which have implemented the Prospectus Directive (a 'Relevant Member
State'), Oasmia has taken no action at the date of this prospectus to offer
shares or subscription rights to the public, which might require the prospectus
to be published in any Relevant Member State. As a consequence thereof, the
share or subscription rights may only be offered in Relevant Member States:
(a) to legal entities which are authorised or permitted to operate in the
financial markets or, if they do not have such authorisation or permission,
whose corporate purpose is solely to invest in securities;
(b) to a legal entity that meets two or more of the following criteria: (1) an
average of at least 250 employees during the last financial year; (2) a total
balance sheet of more than Euro 43 million and (3) an annual net turnover of
more than Euro 50 million, according to its latest annual or consolidated
accounts; or
(c) to such person, investor or other group of persons that an exception from
the prospectus requirement exists in accordance with Article 3(2) in the
Prospectus Directive.
For purposes hereof, the expression 'an offer of shares or subscription rights
to the public' in any Relevant Member State shall mean the communication, in any
form, of sufficient information about the terms of the offer and the shares or
subscription rights that are offered so that an investor can decide whether to
buy securities, as this can be varied in any such Relevant Member State by any
measure implementing the Prospectus Directive in such Member State, and the
expression 'the Prospectus Directive' means Directive 2003/71/EC including all
implementation measures in each respective Relevant Member State.

In connection with the Rights Issue, Carnegie Investment Bank or a
representative for Carnegie Investment Bank may act as a stabilisation manager
and effect transactions to support the exchange price or market price of the
Company's shares, the subscription rights, BTAs or the new shares to balance any
sales pressure. Possible stabilisation will be conducted in accordance with
Regulation (EC) number 2273/2003.
This press release may contain forward-looking information. Forward-looking
information can be identified as information that does not exclusively refer to
the past or current circumstances, or information that may contain words such as
'expected', 'believed', 'estimated', 'planned', 'projected', or 'forecast'.
These statements may involve uncertainties and risks regarding, for example,
product demand and market acceptance, the effect of economic conditions, impact
of competitive products and pricing, currency exchange rates and other risks.
These forward-looking statements reflect the current views of Oasmia's Board of
Directors and management, based on information available to them today, and are
based on a number of assumptions, which are deemed reasonable, but are
inherently uncertain and difficult to predict. Actual results may differ
materially from those expressed or assumed in this forward-looking information.
Oasmia does not intend, nor undertakes any duty, to update any such
forward-looking statements.

News Source: NASDAQ OMX

25.11.2010 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Oasmia Pharmaceutical AB

          SE

Phone:
Fax:
E-mail:
Internet:
ISIN: SE0000722365
WKN:

End of Announcement DGAP News-Service

---